Skip to main content

Advertisement

Table 1 KRAS genotype frequencies in the study population

From: KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study

Study population Genotype Frequency
N %
OR (95% CI) p value
Controls wild (TT) 221/269 (82.2) 1.0  
  variable (TG/GG) 48/269 (17.8)   
Sporadic cases wild (TT) 434/524 (82.8) 0.96 (0.65-1.40) 0.814
  variable (TG/GG) 90/524 (17.2)   
Familial cases wild (TT) 135/165 (81.8) 1.02 (0.62-1.69) 0.929
  variable (TG/GG) 30/165 (18.2)   
BRCA carriers wild (TT) 26/29 (89.7) 0.53 (0.15-1.83) 0.316
  variable (TG/GG) 3/29 (10.3)   
BRCA1 carriers wild (TT) 18/20 (90.0) 0.51 (0.12-2.28) 0.379
  variable (TG/GG) 2/20 (10.0)   
BRCA2 carriers wild (TT) 8/9 (88.9) 0.58 (0.07-4.71) 0.606
  variable (TG/GG) 1/9 (11.1)   
Non-BRCA carriers wild (TT) 109/136 (80.1) 1.14 (0.68-1.93) 0.623
  variable (TG/GG) 27/136 (19.9)